Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 631 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... May 3, 2022 ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in... May 23, 2023 Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... February 2, 2022 To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... February 18, 2021 Load more HOT NEWS First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... How to Tell If Cancer Information on Social Media Is “Fake... Cancer Research UK reports record levels of investment in its spinouts
